MiR‐146a, for example, is known to be increased in T1D and targets inflammation‐related genes such as tumor necrosis factor receptor‐associated factor 6 (TRAF6) and interleukin‐1 receptor‐associated kinase 1 (IRAK1). This evidence concerns the gene TRAF6 and type 1 diabetes mellitus.